Conversely, APOA4 overexpression or recombinant APOA4 administration protects against HFD-induced atherosclerosis by lowering triglycerides, reducing vascular inflammation, and raising HDL cholesterol [337,338,339,340,341,342,343,344]. The gene discussed is APOA4; the disease is atherosclerosis.